HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Das, S. Articles by Leskowitz, S. Search for Related Content PubMed Articles by Das, S. Articles by Leskowitz, S.

The Cellular Basis for Tolerance or Immunity to Bovine -Globulin in Mice¹

From the Department of Pathology, Tufts University School of Medicine, Boston, Massachusetts 02111

Abstract

BALB/c and DBA/2 mice were shown to have markedly different susceptibility to tolerance induction with bovine -globulin (BGG), the latter strain becoming tolerant at doses greater than 0.2 mg, while the former required more than 20 mg. When cells from BALB/c spleens were transferred to lethally irradiated DBA/2 recipients, the animals behaved like the normal DBA/2 in respect to tolerance induction, i.e., doses of 0.2 mg or more of BGG readily produced unresponsiveness. Similarly, when DBA/2 spleen cells were transferred to irradiated BALB/c recipients, behavior toward tolerance induction was like normal BALB/c, i.e., tolerance was not produced with doses less than 20 mg.

Analysis of response to SIII and typing of T cells by appropriate antisera showed that recipients were true chimeras in respect to B and T cells.

It was felt that the behavior of these irradiated reconstituted animals depended on the existence of a radiation-resistant macrophage which, in the case of BALB/c recipients, had the capacity to process small amounts of immunogenic material in BGG to make an immune response before concurrent induction of tolerance by monomeric BGG was complete. This was borne out by the greater capacity of BALB/c mice to filter out immunogenic material in BGG passaged in vivo.

Footnotes

¹ Supported by Grant AI-10895 from the U.S. Public Health Service.